Omeros Reports Up to 99% Reduction in AML-Driving Cells with OncotoX-AML™

Omeros Corporation reported promising results for its new AML treatment, OncotoX-AML. A single dose reduced up to 99% of the early blood cells that can develop into acute myeloid leukemia, while protecting healthy stem cells needed to make blood. The treatment was well tolerated and did not cause the serious side effects often seen with current AML therapies.